Yet its capacity to cause prominent cytotoxicity, block in Akt/MAPK signaling and degradation of IGF-1Rβ merits further analysis in vivo in NSCLC xenografts and in NSCLC patient cells where response biomarkers should be searched for upfront as recently been pointed out as a way to take IGF-R blocking therapies forward to clinical utility [14-18, 20, 32]. Here, IGF1R is linked to non-small cell lung carcinoma.